Loading
CP
CANbridge Pharmaceuticals Inc. - B Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by Geraghty James Arthur, was filed 15 Jan 2026.
CANbridge Pharmaceuticals Inc. - B: what insiders have been doing
This page follows insider dealings at CANbridge Pharmaceuticals Inc. - B as filed with HKEX, a company from the Health Care sector. From 21 October 2025 to 21 October 2026, the disclosure feed for CANbridge Pharmaceuticals Inc. - B logged 1 filing by 1 insider.
Not one open-market sale was filed. On the buying side, 1 insider reported 1 purchase. The amount is not disclosed for 1 filing. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 senior executive.
Compared with its exchange (1,315 companies, median 4 filings), a count of 1 filing is below the norm. Over the whole record (from 2021), the tally stands at 3 purchases and 1 sale.
The last purchase on record was published on 15 January 2026, which is 279 days ago.
In the same sector, recent insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc also feature in our signals. Source: insider filings from HKEX. Past trades are no guide to future returns.
Insider Decl.
25
Thresholds
n/a
Buy Volume
n/a
3 ops. · all time
Sell Volume
n/a
1 ops. · all time
Who traded when
BuySaleGeraghty James Arthur1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 11,111 of 26,283 companies
55.6
score / 100
Value25
Quality86
FCF yld-4.0%
Earn yld1.5%
EV/EBITDA33.6x
ROE·
Gross mgn75%
Net mgn30%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$1.89
Analyst consensus
Income statement
RevenueHK$50M
Gross profitHK$37.3M75% margin
EBITDAHK$29.2M58% margin
Net incomeHK$14.8M-146.4% margin
Valuation
Beta-0.16
Balance sheet & cash
Market capHK$963.5M
Total debtHK$16.1M
Free Cash Flow-HK$38.2M
Profitability & ownership
ROA-41.2%
% insiders40.4%
% institutions9.0%
Last declaration on 15 January 2026
Declarations25 total
300,000 sharesShareXHKGHKEX:DA20260115E00155
Canonical exit: 12 Apr 2026 (T+90)
4,055 sharesShareXHKGHKEX:DA20250109E00352
4,055 sharesShareXHKGHKEX:DA20250109E00356
4,055 sharesShareXHKGHKEX:DA20250109E00355
4,055 sharesShareXHKGHKEX:DA20250109E00354
4,055 sharesShareXHKGHKEX:DA20250109E00353
4,055 sharesShareXHKGHKEX:DA20240715E00410
4,055 sharesShareXHKGHKEX:DA20240614E00014
3,600,000 sharesShareXHKGHKEX:DA20240521E00337
Canonical exit: 8 Jul 2024 (T+90)
4,055 sharesShareXHKGHKEX:DA20240521E00336
4,055 sharesShareXHKGHKEX:DA20240521E00335
4,084 sharesShareXHKGHKEX:DA20240521E00334
620,280 sharesShareXHKGHKEX:DA20240521E00333
4,415 sharesShareXHKGHKEX:DA20240521E00332
52,987 sharesShareXHKGHKEX:DA20240521E00331
4,055 sharesShareXHKGHKEX:DA20240521E00338
4,055 sharesShareXHKGHKEX:DA20240517E00189
2,000,000 sharesShareXHKGHKEX:DA20221117E00199
Canonical exit: 9 Feb 2023 (T+90)
50,000 shares@ HK$0.76100.0% of flowShareXHKGHKEX:DA20220914E00145
8,437,000 sharesShareXHKGHKEX:DA20220110E00227
250,000 sharesShareXHKGHKEX:DA20211220E00014
1,950,000 sharesShareXHKGHKEX:DA20211220E00012
300,000 sharesShareXHKGHKEX:DA20211220E00013
8,437,000 sharesShareXHKGHKEX:DA20211220E00011
51,256,850 sharesShareXHKGHKEX:DA20211220E00010
25 of 25 declarations
About CANbridge Pharmaceuticals Inc. - B
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for rare diseases and cancers. It is listed on the Hong Kong Stock Exchange under the symbol XHKG.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations